drugset / Trial / NCT03167242

Efficacy and Safety of KAF156 in Combination With LUM-SDF in Adults and Children With Uncomplicated Plasmodium Falciparum Malaria

NCT03167242

RandomizedParallel-groupSingle-blindTreatment

Summary

This study was designed to determine the most effective and tolerable dose at the shortest dosing regimen of the investigational drug KAF156 in combination with a solid dispersion formulation of lumefantrine (LUM-SDF) in adult/adolescent and pediatric patients with uncomplicated Plasmodium falciparum malaria. There is unmet medical need for anti-malarial treatment with new mechanism of action to reduce probability of developing resistance, and for duration shorter than 3 days of treatment and/or reduced pill burden.

Timeline

Start
2017-08-02
Primary completion
2021-06-14
Completion
2021-06-28

Drugs

EvaluationDrugModalityDoseRoute
Comparator Artemether-lumefantrine Unknown Oral
Subject Ganaplacide Small molecule 200 mg Oral
Subject Ganaplacide Small molecule 400 mg Oral
Subject Ganaplacide Small molecule 800 mg Oral
Subject lumefantrine Small molecule 480 mg Oral
Subject lumefantrine Small molecule 960 mg Oral